Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis. 1961;14:593–608. https://doi.org/10.1016/0021-9681(61)90118-7.

Article  CAS  PubMed  Google Scholar 

Dorsey ER, de Roulet J, Thompson JP, Reminick JI, Thai A, White-Stellato Z, Beck CA, George BP, Moses H. Funding of US biomedical research, 2003–2008. JAMA. 2010;303:137–43. https://doi.org/10.1001/jama.2009.1987.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baneyx F, Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol. 2004;22:1399–408. https://doi.org/10.1038/nbt1029.

Article  CAS  PubMed  Google Scholar 

Shendure J, Balasubramanian S, Church GM, Gilbert W, Rogers J, Schloss JA, Waterston RH. DNA sequencing at 40: past, present and future. Nature. 2017;550:345–53. https://doi.org/10.1038/nature24286.

Article  CAS  PubMed  Google Scholar 

Hughes SS. Genentech: the beginnings of biotech. Chicago: University of Chicago Press; 2011.

Book  Google Scholar 

Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver N, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022. https://doi.org/10.1038/s41591-022-01819-x.

Article  PubMed  PubMed Central  Google Scholar 

Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021;12:6071. https://doi.org/10.1038/s41467-021-26282-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyman SD, Jacobsen SE. c-Kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood. 1998;91:1101–34.

Article  CAS  PubMed  Google Scholar 

Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650–65. https://doi.org/10.1038/nrc1169.

Article  CAS  PubMed  Google Scholar 

McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000;95:3489–97.

Article  CAS  PubMed  Google Scholar 

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O’Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21. https://doi.org/10.1056/NEJMoa1516192.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien H-F, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(2022):1345–77. https://doi.org/10.1182/blood.2022016867.

Article  CAS  PubMed  Google Scholar 

Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood. 2008;111:2527–37. https://doi.org/10.1182/blood-2007-05-091215.

Article  CAS  PubMed  Google Scholar 

Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13:169–78. https://doi.org/10.1016/S1097-2765(03)00505-7.

Article  CAS  PubMed  Google Scholar 

Schlessinger J. Autoinhibition control. Science. 2003;300:750–2. https://doi.org/10.1126/science.1082024.

Article  CAS  PubMed  Google Scholar 

Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107:3724–6. https://doi.org/10.1182/blood-2005-08-3453.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007;21:439–45. https://doi.org/10.1038/sj.leu.2404508.

Article  CAS  PubMed  Google Scholar 

Levis M, Allebach J, Tse K-F, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885–91. https://doi.org/10.1182/blood.V99.11.3885.

Article  CAS  PubMed  Google Scholar 

O’Farrell A-M, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597–605. https://doi.org/10.1182/blood-2002-07-2307.

Article  CAS  PubMed  Google Scholar 

Kelly LM, Yu J-C, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002;1:421–32. https://doi.org/10.1016/S1535-6108(02)00070-3.

Article  CAS  PubMed  Google Scholar 

Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci. 2014;111:5319–24. https://doi.org/10.1073/pnas.1320661111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312. https://doi.org/10.1038/s41375-018-0357-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zorn JA, Wang Q, Fujimura E, Barros T, Kuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220). PLoS ONE. 2015;10: e0121177. https://doi.org/10.1371/journal.pone.0121177.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19:889–903. https://doi.org/10.1016/S1470-2045(18)30240-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orgueira AM, Raíndo AP, López MC, Rodríguez BA, Arias JÁD, Ferro RF, Vence NA, López ÁB, Blanco AA, Pérez LB, Valentín PM, Pérez MSG, Cerchione C, Martinelli G, Fernández PM, Encinas MMP, López JLB. Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. PLoS ONE. 2021;16: e0247093. https://doi.org/10.1371/journal.pone.0247093.

Article